Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice

@article{Moreno2021LonglastingAV,
  title={Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice},
  author={Ana M. Moreno and Fernando Alem{\'a}n and Glaucilene F. Catroli and Matthew Hunt and Michael Hu and Amir Dailamy and Andrew Pla and Sarah A. Woller and Nathan D Palmer and Udit Parekh and Daniella McDonald and Amanda J. Roberts and Vanessa S. Goodwill and Ian Dryden and Robert F. Hevner and Lauriane Delay and Gilson Gonçalves dos Santos and Tony L. Yaksh and Prashant Mali},
  journal={Science Translational Medicine},
  year={2021},
  volume={13}
}
In situ genome targeting of NaV1.7 via CRISPRs and zinc fingers enables genomically scarless, durable, and nonaddictive management of pain. Repressing pain LATER Opioids are the current standard of care for the treatment of chronic pain. However, they have severe side effects. Recent data have shown that loss-of-function mutations in the sodium channel NaV1.7 cause insensitivity to pain. Here, Moreno et al. developed an epigenetic strategy using CRISPR-dCas9 and zinc fingers called long-lasting… 
Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents
TLDR
184 is a first-in-class protein-protein inhibitor that capitalizes on CRMP2-NaV1.7 regulation to deliver safe analgesia in rodents and was not only antinociceptive in preclinical models of acute and chronic pain but also demonstrated synergy alongside other analgesics—without eliciting addiction, rewarding properties, or neurotoxicity.
Targeted ubiquitination of sensory neuron calcium channels reduces the development of neuropathic pain.
TLDR
Subcutaneous injection is used to express a genetically encoded molecule that blocks HVACCs in sensory neurons in vivo, and it is demonstrated that this approach effectively reduces the onset of neuropathic pain in an animal model of the disease without any observable side effects.
Genetic and epigenetic mechanisms influencing acute to chronic postsurgical pain transitions in pediatrics: Preclinical to clinical evidence
TLDR
A comprehensive review of current preclinical and clinical evidence for genetic and epigenetic mechanisms relevant to pediatric chronic postsurgical pain (CPSP) and pathways identified by adult gene association studies point to potential common mechanisms are presented.
Acupoint Injection of Dextrose Attenuates Chronic Inflammatory Pain In Mice Through Modulation of Transient Receptor Potential V1 Channel Expression
TLDR
These findings suggest that AI can mitigate chronic pain (and sequel such as comorbid depression) by suppressing TRPV1 overexpression in neuronal or microglial cells.
Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets
TLDR
This review outlines the current status and future therapeutic promise of peripherally acting channel modulators and suggests that peripheral voltage-gated cation channels retain their promise as therapeutic targets.
TRPV1 Responses in the Cerebellum Lobules VI, VII, VIII Using Electroacupuncture Treatment for Chronic Pain and Depression Comorbidity in a Murine Model
TLDR
Findings suggest that AS-induced chronic pain and depression comorbidity elicits changes in the cerebellum lobules VI, VII, VIII, which are ameliorated through the use of EA at ST36 via its action on TRPV1 and related molecular pathways.
Autoimmune diseases - New insights into a troublesome field
...
1
2
...

References

SHOWING 1-10 OF 122 REFERENCES
Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain
TLDR
The findings support the idea that ASOs possess the required pharmacodynamic properties, along with a long duration of action beneficial for treating pain, and are effective in the cell populations involved in pain propagation.
Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7
TLDR
It is reported that Nav1.7 deletion has profound effects on gene expression, leading to an upregulation of enkephalin precursor Penk mRNA and met-enkephaline protein in sensory neurons, in contrast, Nav1-null mutant sensory neurons show no upregulated PenK mRNA expression.
MicroRNA-182 Alleviates Neuropathic Pain by Regulating Nav1.7 Following Spared Nerve Injury in Rats
TLDR
It is concluded that miR-182 can alleviate SNI- induced neuropathic pain through regulating Nav1.7 in rats and reducing the hypersensitivity to mechanical stimulus in naïve rats.
Virus-mediated shRNA Knockdown of Nav1.3 in Rat Dorsal Root Ganglion Attenuates Nerve Injury-induced Neuropathic Pain.
TLDR
The data show that direct DRG injection provides a model that can be used for proof-of-principle studies in chronic pain with respect to peripheral delivery route of gene transfer constructs, high transduction efficiency, flexibility in terms of segmental localization, and limited behaviors of the surgical procedure.
Synergistic regulation of serotonin and opioid signaling contributes to pain insensitivity in Nav1.7 knockout mice
TLDR
It is found that the absence of this channel altered the signaling efficiency of G protein–coupled receptors (GPCRs) in the peripheral pain-sensing neurons of the dorsal root ganglia, and genetic loss of the voltage-gated sodium channel Nav1.7 results in lifelong insensitivity to pain in mice and humans.
The mechanism of analgesia in NaV1.7 null mutants
TLDR
It is demonstrated that NaV1.7 knockout mice have essentially normal nociceptor activity using in vivo calcium imaging and extracellular recording, and opioid-dependent inhibition of neurotransmitter release is the principal mechanism of NaV 1.7 null analgesia in mice and humans.
MicroRNA-30b regulates expression of the sodium channel Nav1.7 in nerve injury-induced neuropathic pain in the rat
Voltage-gated sodium channels, which are involved in pain pathways, have emerged as major targets for therapeutic intervention in pain disorders. Nav1.7, the tetrodotoxin-sensitive voltage-gated
Virus-Mediated Knockdown of Nav1.3 in Dorsal Root Ganglia of STZ-Induced Diabetic Rats Alleviates Tactile Allodynia
TLDR
A validated recombinant adeno-associated virus-shRNA-Nav1.3 vector to knockdown expression is used, via a clinically applicable intrathecal injection method, to offer a novel gene therapy approach for addressing chronic diabetic neuropathic pain.
...
1
2
3
4
5
...